Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (71-80 of 279) with videos related to

Pageof 28
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 19, 2019
Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onsetGuoqiao Wang, Dean Coble, Eric M McDade, et al.
Annals of Neurology|March 17, 2007
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutationJohn S K Kauwe, Sarah Jacquart, Sumi Chakraverty, et al.
Acta Neuropathologica|January 13, 2016
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation statusLaura Piccio, Yuetiva Deming, Jorge L Del-Águila, et al.
JAMA Neurology|March 13, 2013
Sleep quality and preclinical Alzheimer diseaseYo-El S Ju, Jennifer S McLeland, Cristina D Toedebusch, et al.
Journal of Alzheimer'S Disease : JAD|April 24, 2023
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical AssessmentCharles D Chen, Maria Rosana Ponisio, Jordan A Lang, et al.
Proteomics. Clinical Applications|December 8, 2010
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's diseaseYan Hu, Ava Hosseini, John S K Kauwe, et al.
Alzheimer Disease and Associated Disorders|March 27, 2018
Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation AbilitiesSamantha Allison, Ganesh M Babulal, Sarah H Stout, et al.
Neurobiology of Aging|June 19, 2016
NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkersStephanie J B Vos, Brian A Gordon, Yi Su, et al.
Archives of Neurology|December 17, 2009
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer diseaseJohn C Morris, Catherine M Roe, Elizabeth A Grant, et al.
Neuropsychology|February 17, 2017
Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficitsPeter R Millar, David A Balota, Geoffrey B Maddox, et al.
Pageof 28

Showing results (71-80 of 279) with videos related to

Sort By:
Pageof 28
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 19, 2019
Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onsetGuoqiao Wang, Dean Coble, Eric M McDade, et al.
Annals of Neurology|March 17, 2007
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutationJohn S K Kauwe, Sarah Jacquart, Sumi Chakraverty, et al.
Acta Neuropathologica|January 13, 2016
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation statusLaura Piccio, Yuetiva Deming, Jorge L Del-Águila, et al.
JAMA Neurology|March 13, 2013
Sleep quality and preclinical Alzheimer diseaseYo-El S Ju, Jennifer S McLeland, Cristina D Toedebusch, et al.
Journal of Alzheimer'S Disease : JAD|April 24, 2023
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical AssessmentCharles D Chen, Maria Rosana Ponisio, Jordan A Lang, et al.
Proteomics. Clinical Applications|December 8, 2010
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's diseaseYan Hu, Ava Hosseini, John S K Kauwe, et al.
Alzheimer Disease and Associated Disorders|March 27, 2018
Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation AbilitiesSamantha Allison, Ganesh M Babulal, Sarah H Stout, et al.
Neurobiology of Aging|June 19, 2016
NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkersStephanie J B Vos, Brian A Gordon, Yi Su, et al.
Archives of Neurology|December 17, 2009
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer diseaseJohn C Morris, Catherine M Roe, Elizabeth A Grant, et al.
Neuropsychology|February 17, 2017
Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficitsPeter R Millar, David A Balota, Geoffrey B Maddox, et al.
Pageof 28